<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01184911</url>
  </required_header>
  <id_info>
    <org_study_id>CDC5972</org_study_id>
    <nct_id>NCT01184911</nct_id>
  </id_info>
  <brief_title>Sulphadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda</brief_title>
  <acronym>SP IPTp</acronym>
  <official_title>Assessment of the Efficacy of Sulphadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uganda Malaria Surveillance Project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effectiveness of sulfadoxine-pyrimethamine (SP) as intermittent preventive treatment in
      pregnancy in malaria-endemic areas the effectiveness and efficacy of SP may be compromised by
      increased SP resistance. This study will evaluate the efficacy of SP by giving SP to
      asymptomatic parasitemic pregnant women and following them to determine the rates of parasite
      clearance.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Research plan changed; no longer conducting clinical trial.
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parasite clearance</measure>
    <time_frame>42 days</time_frame>
    <description>Clearance of parasites in pregnant women with asymptomatic parasitemia after administration of SP</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Intermittent Preventive Treatment</condition>
  <condition>Placental Malaria</condition>
  <arm_group>
    <arm_group_label>SP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asymptomatic parasitemic pregnant women who receive the standard dose of sulfadoxine-pyrimethamine for prevention of placental malaria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfadoxine-pyrimethamine</intervention_name>
    <description>Sulfadoxine-pyrimethamine tablets, once</description>
    <arm_group_label>SP</arm_group_label>
    <other_name>Kamsidar, Fansidar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  16-26 weeks gestation based on LMP or ultrasound or fundal height

          -  Axillary temperature &lt;37.5 degrees C

          -  Informed consent

          -  HIV status known and negative

          -  Blood smear positive for falciparum malaria

        Exclusion Criteria:

          -  History of hypersensitivity reaction to SP or components of SP

          -  Axillary temperature â‰¥37.5 degrees C

          -  History of receipt of antimalarials or antibiotics with antimalarial activity* in the
             past month

          -  Residence &gt; 30 km from the ANC clinic or unwillingness to return for follow-up visits

          -  Hemoglobin level &lt; 5 gm/dL

               -  These medications include all antimalarials, rifampin, doxycycline, clindamycin,
                  tetracycline, erythromycin, azithromycin, chloramphenicol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronica Ades, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Filler, MD, DTM&amp;H</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moses Kamya, MBChB, MMed, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uganda Malaria Surveillance Project</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Infectious Disease Research Center</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2010</study_first_submitted>
  <study_first_submitted_qc>August 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <last_update_submitted>March 3, 2015</last_update_submitted>
  <last_update_submitted_qc>March 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <name_title>Grant Dorsey</name_title>
    <organization>University of California San Francisco</organization>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

